191 related articles for article (PubMed ID: 33216211)
1. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
[TBL] [Abstract][Full Text] [Related]
2. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
3. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
4. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
[TBL] [Abstract][Full Text] [Related]
5. Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Sobhani N; Roviello G; Pivetta T; Ianza A; Bonazza D; Zanconati F; Giudici F; Bottin C; Corona SP; Guglielmi A; Rizzardi C; Milione M; Cortale M; Confalonieri M; Generali D
Mol Biol Rep; 2019 Jun; 46(3):2713-2720. PubMed ID: 30840203
[TBL] [Abstract][Full Text] [Related]
6. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and clinicopathological utility of programmed death-ligand 1 in malignant pleural mesothelioma: A meta-analysis.
Zhang F; Gong W
Int Immunopharmacol; 2020 Jun; 83():106481. PubMed ID: 32339986
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
Nguyen BH; Montgomery R; Fadia M; Wang J; Ali S
Asia Pac J Clin Oncol; 2018 Feb; 14(1):69-73. PubMed ID: 29105302
[TBL] [Abstract][Full Text] [Related]
9. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
10. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S; Ponce-Aix S; Zugazagoitia J; Sansano I; Enguita A; Navarro-Mendivil A; Martinez-Marti A; Martinez P; Felip E
PLoS One; 2015; 10(3):e0121071. PubMed ID: 25774992
[TBL] [Abstract][Full Text] [Related]
11. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
[TBL] [Abstract][Full Text] [Related]
12. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Inaguma S; Lasota J; Wang Z; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Miettinen M
Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
[TBL] [Abstract][Full Text] [Related]
13. [Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1543-6. PubMed ID: 25146741
[TBL] [Abstract][Full Text] [Related]
14. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
15. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
16. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
17. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S; Ponce-Aix S; Pardo-Aranda N; Navarro-Mendivil A; Martinez-Marti A; Zugazagoitia J; Sansano I; Montoro MA; Enguita A; Felip E
Lung Cancer; 2016 Jun; 96():1-6. PubMed ID: 27133741
[TBL] [Abstract][Full Text] [Related]
18. Malignant Mesothelioma Effusions Are Infiltrated by CD3
Khanna S; Thomas A; Abate-Daga D; Zhang J; Morrow B; Steinberg SM; Orlandi A; Ferroni P; Schlom J; Guadagni F; Hassan R
J Thorac Oncol; 2016 Nov; 11(11):1993-2005. PubMed ID: 27544053
[TBL] [Abstract][Full Text] [Related]
19. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T; Chamoto K; Suzuki S; Kanemura H; Mitani S; Tanaka K; Kawakami H; Kishimoto Y; Haku Y; Ito K; Sato T; Suminaka C; Yamaki M; Chiba Y; Yaguchi T; Omori K; Kobayashi T; Nakagawa K; Honjo T; Hayashi H
Front Immunol; 2023; 14():1325462. PubMed ID: 38149256
[TBL] [Abstract][Full Text] [Related]
20. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy.
Okita R; Mimura-Kimura Y; Kawamoto N; Yamamoto N; Umeda M; Okada M; Inokawa H; Mimura Y; Murakami T; Nakata M; Okabe K
Cancer Immunol Immunother; 2023 Apr; 72(4):865-879. PubMed ID: 36115921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
